Physician profile

Beth L Thurberg

Anatomic Pathology · Framingham, MA

NPI 1801820634

$142,058.19

in general payments reported to CMS, 2019-2025

6 companies · $14K in 2025

The $14K reported for 2025 was more than what 95% of Anatomic Pathology providers received nationally (typical 2025 total: $110).

See the full distribution for Anatomic Pathology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$80,537.00
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$9,307.50
Food and Beverage$320.15

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ultragenyx Pharmaceutical INC. $71,941.54 2020-2025
Alexion Pharmaceuticals, INC. $30,250.00 2024
Chiesi USA, INC. $17,450.00 2024-2025
Genzyme Corporation $12,390.65 2021-2025
Sanofi US Services INC. $8,626.00 2021-2023
Spark Therapeutics, INC. $1,400.00 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Beth L Thurberg

$142,058.19

in general payments reported 2019-2025

Years
2020-2025
Top company
Ultragenyx Pharmaceutical INC.
Context
The $14K reported for 2025 was more than what 95% of Anatomic Pathology providers received nationally (typical 2025 total: $110).

https://glasscript.com/doctor/386100/beth-l-thurberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.